BCRX BioCryst Pharmaceuticals, Inc. Stock Quote

BCRX [NASD]

Index	-	P/E	-	EPS (ttm)	-1.09	Insider Own	0.80%	Shs Outstand	176.69M	Perf Week	6.26%
Market Cap	2.16B	Forward P/E	-	EPS next Y	-0.73	Insider Trans	-12.40%	Shs Float	175.06M	Perf Month	11.01%
Income	-182.80M	PEG	-	EPS next Q	-0.27	Inst Own	69.00%	Short Float	13.34%	Perf Quarter	31.77%
Sales	17.80M	P/S	121.33	EPS this Y	-16.00%	Inst Trans	-4.46%	Short Ratio	3.37	Perf Half Y	243.30%
Book/sh	-0.11	P/B	-	EPS next Y	29.10%	ROA	-84.80%	Target Price	14.56	Perf Year	249.28%
Cash/sh	1.68	P/C	7.19	EPS next 5Y	19.90%	ROE	-773.60%	52W Range	2.75 - 14.24	Perf YTD	61.74%
Dividend	-	P/FCF	-	EPS past 5Y	-13.10%	ROI	-69.30%	52W High	-13.87%	Beta	2.65
Dividend %	-	Quick Ratio	3.00	Sales past 5Y	-18.10%	Gross Margin	90.60%	52W Low	346.00%	ATR	0.84
Employees	246	Current Ratio	3.10	Sales Q/Q	-89.90%	Oper. Margin	-	RSI (14)	61.58	Volatility	7.00% 6.97%
Optionable	Yes	Debt/Eq	-	EPS Q/Q	-	Profit Margin	-	Rel Volume	0.32	Prev Close	12.05
Shortable	Yes	LT Debt/Eq	-	Earnings	Feb 25 BMO	Payout	-	Avg Volume	6.93M	Price	12.27
Recom	2.00	SMA20	16.59%	SMA50	10.24%	SMA200	78.76%	Volume	216,265	Change	1.78%

Mar-01-21

Initiated

Cowen

Outperform

$16

Sep-29-20

Resumed

JP Morgan

Overweight

Jun-17-20

Initiated

BTIG Research

Neutral

May-05-20

Upgrade

Barclays

Equal Weight → Overweight

Nov-15-19

Upgrade

BofA/Merrill

Neutral → Buy

$5 → $4

May-24-19

Downgrade

RBC Capital Mkts

Outperform → Sector Perform

$16 → $4.50

Nov-16-18

Resumed

Piper Jaffray

Overweight

$15

Aug-08-18

Resumed

JP Morgan

Overweight

Jul-17-18

Upgrade

BofA/Merrill

Underperform → Neutral

Jun-22-18

Initiated

Seaport Global Securities

Neutral

Jan-02-18

Upgrade

RBC Capital Mkts

Sector Perform → Outperform

Dec-20-17

Initiated

Barclays

Equal Weight

Sep-15-17

Initiated

RBC Capital Mkts

Sector Perform

Sep-06-17

Upgrade

JP Morgan

Neutral → Overweight

Sep-06-17

Upgrade

Jefferies

Hold → Buy

Feb-16-17

Initiated

Ladenburg Thalmann

Buy

$11

Aug-12-16

Upgrade

Piper Jaffray

Neutral → Overweight

Aug-04-16

Downgrade

JMP Securities

Mkt Outperform → Mkt Perform

Feb-09-16

Reiterated

FBR Capital

Outperform

$18 → $6

Feb-09-16

Downgrade

Needham

Buy → Hold

Apr-22-21 07:00AM	BioCryst to Report First Quarter 2021 Financial Results on May 6 GlobeNewswire
Apr-20-21 09:30AM	Is BCRX Stock A Buy or Sell? Insider Monkey
Apr-14-21 03:42PM	Why BioCryst Pharmaceuticals Stock Is Popping Today Motley Fool +5.21%
08:15AM	BioCryst Announces Approval of Japanese NHI Price Listing of ORLADEYO (berotralstat) for Prophylactic Treatment of Hereditary Angioedema GlobeNewswire
Apr-08-21 01:19AM	The BioCryst Pharmaceuticals (NASDAQ:BCRX) Share Price Is Up 421% And Shareholders Are Delighted Simply Wall St.
Apr-07-21 07:00AM	BioCryst to Present at 20th Annual Needham Virtual Healthcare Conference GlobeNewswire
Mar-24-21 12:16PM	BioCryst: Sometimes Good News Isnt Good Enough TipRanks
Mar-22-21 01:27PM	BioCryst Technical Levels To Watch Benzinga -10.88%
08:00AM	BioCrysts Oral Factor D Inhibitor, BCX9930, Advancing to Pivotal Trials in PNH Following Successful Proof of Concept Trial GlobeNewswire
Mar-19-21 07:00AM	BioCryst Appoints Helen Thackray, M.D., as Chief Research and Development Officer GlobeNewswire
Mar-15-21 07:00AM	BioCryst to Host Virtual R&D Day on March 22, 2021 GlobeNewswire +6.65%
Mar-11-21 08:30AM	Early Access to BioCrysts Berotralstat Granted for HAE Patients in France GlobeNewswire
Mar-02-21 07:00AM	BioCryst Submits Marketing Authorization Application for UK Approval of ORLADEYO (berotralstat), an Oral, Once-daily Therapy to Prevent Attacks in Patients with Hereditary Angioedema GlobeNewswire
Mar-01-21 02:00PM	Why BioCryst Pharmaceuticals Stock Is Popping Today Motley Fool +11.13%
Feb-26-21 06:31AM	BioCryst's Orladeyo Wins EU Positive Opinion For Hereditary Angioedema Benzinga
Feb-25-21 04:15PM	BioCryst Receives Positive CHMP Opinion for ORLADEYO (berotralstat), an Oral, Once-daily Therapy to Prevent Attacks in Patients with Hereditary Angioedema GlobeNewswire -11.35%
02:10PM	Why BioCryst Pharmaceuticals Stock Is Falling Today Motley Fool
01:31PM	BioCryst Pharmaceuticals (BCRX) Q4 2020 Earnings Call Transcript Motley Fool
07:00AM	BioCryst Reports Fourth Quarter and Full Year 2020 Financial Results and Upcoming Key Milestones GlobeNewswire
06:30AM	BioCryst Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Feb-18-21 07:00AM	BioCryst to Present at Upcoming Investor Conferences GlobeNewswire
Feb-11-21 07:00AM	BioCryst to Report Fourth Quarter and Full Year 2020 Financial Results on February 25 GlobeNewswire
Feb-09-21 07:15AM	BioCryst to Present Data at 2021 American Academy of Allergy, Asthma & Immunology Annual Meeting GlobeNewswire
Feb-08-21 10:11AM	10 Best Small-Cap Biotech Stocks Under $10 in 2021 Insider Monkey
Feb-07-21 01:27AM	What Kind Of Shareholders Hold The Majority In BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Shares? Simply Wall St.
Feb-03-21 07:00AM	BioCryst Announces FDA Approval of Supplemental New Drug Application for RAPIVAB® Expanding Patient Population to Include Children Six Months and Older GlobeNewswire
Feb-02-21 11:37AM	The GameStop frenzy convinced more people to search 'how to buy stocks' than last year's surge Yahoo Finance -11.14%
07:00AM	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Feb-01-21 04:54PM	Reddit Traders Declare BioWar as Shorted Biotechs Soar Bloomberg +39.08%
Jan-28-21 08:34AM	Implied Volatility Surging for BioCryst (BCRX) Stock Options Zacks
Jan-25-21 09:28AM	BioCryst (BCRX) Wins Japanese Approval for HAE Drug Orladeyo Zacks
Jan-22-21 10:58AM	Looking Into Biocryst Pharmaceuticals's Return On Capital Employed Benzinga
07:00AM	BioCryst Announces Approval of ORLADEYO (berotralstat) in Japan for the Prophylactic Treatment of Hereditary Angioedema GlobeNewswire
Jan-07-21 07:00AM	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Jan-06-21 07:00AM	BioCryst to Present at 39th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-23-20 10:15AM	Biotech Stock Roundup: PFE/BNTX Vaccine Authorized in Europe, Updates From AMGN, & More Zacks
10:12AM	BioCryst (BCRX) Provides Updates on Galidesivir, Shares Fall Zacks
07:13AM	2 Ultra-High-Growth Healthcare Stocks That Are Just Getting Started Motley Fool
Dec-22-20 11:42AM	Why BioCryst Pharmaceuticals Stock Is Sinking Today Motley Fool -8.55%
07:00AM	BioCryst Provides Update on Galidesivir Program GlobeNewswire
Dec-21-20 10:01AM	The Zacks Analyst Blog Highlights: Quidel, Halozyme Therapeutics, Teladoc Health, Acceleron Pharma and BioCryst Pharmaceuticals Zacks
07:00AM	BioCryst Announces Positive Phase 1 Results with BCX9250, an Oral ALK-2 Inhibitor for Treatment of Fibrodysplasia Ossificans Progressiva GlobeNewswire
Dec-18-20 08:28PM	Is BCRX A Good Stock To Buy Now According To Hedge Funds? Insider Monkey
Dec-16-20 07:00AM	BioCryst Announces U.S. Availability of ORLADEYO (berotralstat) for the Treatment of Hereditary Angioedema GlobeNewswire
Dec-11-20 07:00AM	BioCryst to Present at JMP Securities Hematology Summit GlobeNewswire +6.14%
Dec-09-20 01:10PM	Biotech Stock Roundup: ASH Data in Focus, CRIS, BCRX Surge & More Pipeline News Zacks -5.22%
09:56AM	BioCryst (BCRX) in Focus: Stock Moves 6.1% Higher Zacks
Dec-08-20 11:50PM	BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Insiders Increased Their Holdings Simply Wall St. +6.09%
Dec-07-20 08:45AM	Royalty Pharma Acquires Royalty Interest in ORLADEYO and BCX9930 From BioCryst Pharmaceuticals GlobeNewswire +18.36%
08:40AM	BioCryst Announces $325 Million of Funding from Royalty Pharma and Athyrium Capital Management GlobeNewswire
Dec-06-20 10:00AM	BioCrysts Oral Factor D Inhibitor (BCX9930) Shows High Potency and Specificity for Alternative Pathway of Complement GlobeNewswire
Dec-04-20 12:59PM	Why BioCryst, Moderna And More Are Moving Today Benzinga +18.79%
12:25PM	Why BioCryst Stock Is Crushing It Today Motley Fool
10:02AM	Looking Into Biocryst Pharmaceuticals's Return On Capital Employed Benzinga
09:00AM	BioCryst (BCRX) Wins FDA Approval for HAE Drug Orladeyo Zacks
Dec-03-20 08:45PM	BioCryst Announces FDA Approval of ORLADEYO (berotralstat), First Oral, Once-daily Therapy to Prevent Attacks in Hereditary Angioedema Patients GlobeNewswire
11:59AM	Is BioCryst Stock a Buy Ahead of the FDAs Orladeyo Decision? Analyst Weighs In TipRanks
10:34AM	Are Options Traders Betting on a Big Move in BioCryst Pharmaceuticals (BCRX) Stock? Zacks
Dec-01-20 04:15PM	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Nov-30-20 07:00AM	Allergy Publishes Results from BioCrysts APeX-J Trial of Oral, Once-Daily Berotralstat for the Prevention of HAE Attacks GlobeNewswire
Nov-20-20 07:00AM	BioCryst to Present at Upcoming Virtual Investment Conferences GlobeNewswire
Nov-13-20 07:59AM	What Does BioCryst Pharmaceuticals's Debt Look Like? Benzinga
07:02AM	BioCryst Presents Data Showing Sustained Attack Rate Reductions, Improved Patient Satisfaction and Quality of Life for HAE Patients Taking Berotralstat in APeX-2 Trial GlobeNewswire
07:00AM	BioCryst Presents New Data Highlighting Burden of Therapy with Current Injectable Prophylaxis Medication for HAE GlobeNewswire
Nov-12-20 07:00AM	BioCryst to Present Data at the 2020 ASH Annual Meeting GlobeNewswire
Nov-07-20 08:01AM	BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock? Simply Wall St.
Nov-05-20 11:01PM	BioCryst Pharmaceuticals (BCRX) Q3 2020 Earnings Call Transcript Motley Fool
09:25AM	BioCryst Pharmaceuticals (BCRX) Reports Q3 Loss, Tops Revenue Estimates Zacks
07:00AM	BioCryst Reports Third Quarter 2020 Financial Results and Upcoming Key Milestones GlobeNewswire
Nov-02-20 04:15PM	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Oct-30-20 08:15AM	MHRA Grants HAE Patients Early Access to BioCrysts Berotralstat in United Kingdom GlobeNewswire
Oct-29-20 12:35PM	BioCryst Pharmaceuticals (BCRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks
Oct-28-20 07:31AM	A Look At BioCryst Pharmaceuticals' (NASDAQ:BCRX) CEO Remuneration Simply Wall St.
07:00AM	Biocryst to Present Abstracts at Annual Scientific Meeting of American College of Allergy, Asthma & Immunology GlobeNewswire
Oct-22-20 04:15PM	BioCryst to Report Third Quarter 2020 Financial Results on November 5 GlobeNewswire +6.96%
07:00AM	Journal of Allergy and Clinical Immunology Publishes Results from BioCrysts APeX-2 Pivotal Trial of Oral, Once-Daily Berotralstat for the Prevention of HAE Attacks GlobeNewswire
Oct-07-20 08:34AM	Is the Options Market Predicting a Spike in BioCryst Pharmaceuticals (BCRX) Stock? Zacks +7.76%
Oct-05-20 04:15PM	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire +8.16%
Sep-30-20 07:00AM	BioCrysts Oral Factor D Inhibitor, BCX9930, Shows Clinical Benefit as Monotherapy Through 400 mg bid in Treatment-naïve PNH Patients GlobeNewswire -10.43%
Sep-28-20 03:09PM	Hedge Funds Keep Buying BioCryst Pharmaceuticals, Inc. (BCRX) Insider Monkey
Sep-22-20 07:25AM	Does BioCryst Pharmaceuticals (NASDAQ:BCRX) Have A Healthy Balance Sheet? Simply Wall St.
Sep-08-20 07:00AM	BioCryst to Present at 22nd Annual H.C. Wainwright Global Investment Conference GlobeNewswire
Sep-03-20 04:15PM	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire -5.67%
07:00AM	U.S. Government Exercises Option To Purchase Additional RAPIVAB® from BioCryst for Delivery to Strategic National Stockpile GlobeNewswire
Aug-31-20 09:29AM	NIAID Awards BioCryst New $44 Million Contract to Advance Development of Galidesivir GlobeNewswire
07:00AM	FDA Grants Orphan Drug Designation for BCX9930 in PNH GlobeNewswire
Aug-17-20 11:41AM	BioCryst Pharmaceuticals' (NASDAQ:BCRX) Shareholders Are Down 62% On Their Shares Simply Wall St. +5.23%
Aug-13-20 01:48PM	Here's Why BioCryst Pharmaceuticals Jumped Higher Today Motley Fool +15.87%
Aug-11-20 08:54AM	Do Options Traders Know Something About BioCryst Pharmaceuticals (BCRX) Stock We Don't? Zacks
Aug-06-20 09:55AM	BioCryst Pharmaceuticals (BCRX) Reports Q2 Loss, Misses Revenue Estimates Zacks
07:00AM	BioCryst Reports Second Quarter 2020 Financial Results and Upcoming Key Milestones GlobeNewswire
Aug-04-20 07:00AM	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Aug-03-20 11:19AM	Is BioCryst Pharmaceuticals Stock a Buy? Motley Fool +8.11%
07:00AM	FDA Grants Fast Track Designation for BCX9930 in PNH GlobeNewswire
Jul-23-20 07:00AM	BioCryst to Report Second Quarter 2020 Financial Results on August 6 GlobeNewswire
Jul-18-20 07:16PM	Did Hedge Funds Make The Right Call On BioCryst Pharmaceuticals, Inc. (BCRX) ? Insider Monkey
Jul-15-20 11:35AM	Better Buy: Moderna vs. BioCryst Pharmaceuticals Motley Fool
Jul-07-20 02:43PM	BioCryst Pharmaceuticals Jumped Higher Today; Here's Why Investors May Be Wrong Motley Fool +9.29%
11:57AM	What You Need To Know About BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Investor Composition Simply Wall St.
11:30AM	Is BioCryst Pharmaceuticals (BCRX) Outperforming Other Medical Stocks This Year? Zacks

BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase I clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. BioCryst Pharmaceuticals, Inc. has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. The company was founded in 1986 and is headquartered in Durham, North Carolina.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Jones Michael L	Exec. Director, Finance - PAO	Mar 18	Option Exercise	3.51	4,500	15,795	5,348	Mar 22 04:19 PM
Sheridan William P	Senior VP - CMO	Feb 22	Option Exercise	4.15	41,250	171,188	52,725	Feb 24 04:34 PM
Sheridan William P	Senior VP - CMO	Feb 22	Sale	11.57	41,250	477,262	11,475	Feb 24 04:34 PM
Babu Yarlagadda S	Senior VP - Drug Discovery	Feb 19	Option Exercise	4.15	50,000	207,500	205,587	Feb 23 04:25 PM
Stonehouse Jon P	President & CEO	Dec 15	Option Exercise	4.15	134,278	557,254	918,364	Dec 17 04:20 PM
Stonehouse Jon P	President & CEO	Dec 15	Sale	8.32	134,278	1,117,193	784,086	Dec 17 04:20 PM
Barnes Alane P	Senior VP, Chief Legal Officer	Dec 11	Option Exercise	4.15	13,741	57,025	121,802	Dec 15 05:35 PM
Barnes Alane P	Senior VP, Chief Legal Officer	Dec 11	Sale	7.96	13,741	109,378	108,061	Dec 15 05:35 PM
Barnes Alane P	Senior VP, Chief Legal Officer	Dec 04	Option Exercise	4.15	13,741	57,025	121,802	Dec 08 04:12 PM
Barnes Alane P	Senior VP, Chief Legal Officer	Dec 04	Sale	6.23	13,741	85,606	108,061	Dec 08 04:12 PM
Doyle Anthony	Chief Financial Officer	Aug 11	Buy	4.08	54,000	220,320	54,000	Aug 12 04:31 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience